GlassScriptPhysician profile
Bailey P Shredl
NPI 1508539891
$5,950.74
in general payments reported to CMS, 2019-2025
55 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,477 · 2024: $2,567 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,939 · Education: $11.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,938.86 |
| Education | $11.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $540.98 | 2023-2025 | |
| Janssen Biotech, INC. | $455.94 | 2023-2025 | Erleada, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $363.76 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $358.27 | 2023-2025 | Tecentriq, Venclexta, Polivy |
| Astrazeneca Pharmaceuticals LP | $305.18 | 2023-2025 | Enhertu, Imfinzi, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $302.59 | 2023-2025 | Libtayo |
| Pfizer INC. | $265.39 | 2023-2025 | |
| Daiichi Sankyo INC. | $195.78 | 2023-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $194.24 | 2023-2025 | Opdivo, Opdualag, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $185.14 | 2023-2025 | Alunbrig, Fruzaqla, Iclusig |
| Lilly USA, LLC | $168.11 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $167.53 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $164.53 | 2023-2025 | |
| Abbvie INC. | $157.72 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.00 | 2023-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $135.35 | 2023-2025 | Zoladex, Xermelo |
| Celgene Corporation | $133.52 | 2023-2025 | Reblozyl, Pomalyst, Breyanzi |
| Emd Serono, INC. | $131.00 | 2023-2025 | Bavencio |
| Exelixis INC. | $108.44 | 2023-2025 | Cabometyx |
| Taiho Oncology, INC. | $103.40 | 2023-2025 | |
| Array Biopharma INC | $79.24 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $76.71 | 2023-2025 | |
| Glaxosmithkline, LLC. | $74.73 | 2024-2025 | Ojjaara, Blenrep, Zejula |
| Genzyme Corporation | $74.40 | 2023-2025 | |
| Gilead Sciences, INC. | $67.62 | 2024-2025 | Trodelvy |
| Seagen INC. | $66.75 | 2023 | Tukysa, Adcetris |
| Geron Corporation | $66.07 | 2025 | Rytelo |
| Blueprint Medicines Corporation | $61.73 | 2023-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.36 | 2023-2024 | Gilotrif |
| Emmaus Medical, INC. | $50.97 | 2023 | Endari |
| Recordati_rare_diseases_inc. | $49.17 | 2025 | Enjaymo, Sylvant |
| Menarini Silicon Biosystems, INC. | $45.19 | 2024-2025 | |
| Stemline Therapeutics INC. | $43.58 | 2024-2025 | Orserdu |
| Beigene USA, INC. | $42.79 | 2024-2025 | Tevimbra |
| Genmab U.S., INC. | $40.20 | 2023-2024 | Epkinly |
| Sobi, INC | $40.10 | 2023-2024 | |
| Puma Biotechnology, INC. | $40.01 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $39.91 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $36.61 | 2023-2024 | Orgovyx |
| Amgen INC. | $31.24 | 2023 | Nplate, Vectibix, Xgeva |
| Coherus Oncology, INC. | $30.87 | 2023-2024 | |
| Beone Medicines USA, INC. | $23.83 | 2025 | Tevimbra |
| Pinnacle Biologics, INC | $22.59 | 2025 | Photofrin |
| G1 Therapeutics, INC. | $22.02 | 2023 | Cosela |
| Apellis Pharmaceuticals, INC. | $21.21 | 2023 | Empaveli |
| Adc Therapeutics America, INC. | $20.89 | 2023 | |
| Syndax Pharmaceuticals, INC. | $19.89 | 2025 | |
| Octapharma USA, INC. | $19.27 | 2024 | Octagam Immune Globulin (Human) |
| Aveo Pharmaceuticals, INC. | $18.52 | 2025 | |
| Mirati Therapeutics, INC. | $18.52 | 2024 | Krazati |
| Kyowa Kirin, INC. | $18.09 | 2023 | Poteligeo |
| Genentech, INC. | $17.76 | 2024 | Columvi, Alecensa, Itovebi |
| Melinta Therapeutics, LLC | $16.29 | 2024 | Kimyrsa, Rezzayo |
| Pharmacosmos Therapeutics INC. | $15.97 | 2024 | Cosela |
| Pharmaand Gmbh | $11.77 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Shredl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.